Drugs / BRII-179
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06650852 | Oct 2024 → Jul 2026 overdue | chronic hepatitis B virus infection | Brii Biosciences Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06491563 | Aug 2024 → Dec 2026 expected | chronic hepatitis B virus infection | Brii Biosciences Limited | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04749368 | Apr 2021 → Jul 2023 | chronic hepatitis B virus infection | Brii Biosciences Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2026-07-03 | Brii Biosciences Limited | Results Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B briibio.com ↗
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies |
| 2026-05-27 | Brii Biosciences Limited | Results Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV briibio.com ↗
Data from Cohort 4 suggested that participants responding to prior BRII-179 treatment achieved the most robust functional cure outcomes, further supporting its potential clinical benefit |
| 2026-04-26 | Brii Biosciences Limited | Results Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026 briibio.com ↗
Participants achieving HBsAg loss with pegylated interferon alfa ( PEG -IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. |
| 2025-11-10 | Brii Biosciences Limited | Results Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179’s Potential as a Curative Treatment for Chronic Hepatitis B briibio.com ↗
Cohort 4 follow-up confirms durable h epatitis B surface antigen ( HBsAg ) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs respon ders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) |
| 2025-11-07 | Brii Biosciences Limited | Results Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine briibio.com ↗ |
| 2025-05-08 | Brii Biosciences Limited | Results Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179’s Role in Advancing Higher HBsAg Loss briibio.com ↗ |
| 2025-04-24 | Brii Biosciences Limited | Results Brii Bio to Present Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study in Participants with Chronic Hepatitis B Virus Infection at EASL 2025 briibio.com ↗ |
| 2025-03-30 | Brii Biosciences Limited | Results Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification briibio.com ↗
Preliminary d ata from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT |
| 2024-06-07 | Brii Biosciences Limited | Results Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 briibio.com ↗
Pre-S1-specific T cell response targeting a region adjacent to sodium taurocholate cotransporting polypeptide (NTCP) was identified to be associated with high levels of HBsAg reduction in some participants receiving BRII-835 (elebsiran) and BRII-179. |
| 2023-11-10 | Brii Biosciences Limited | Results Brii Bio to Present New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD’s The Liver Meeting ® 2023 briibio.com ↗
Phase 2 interim results: BRII-179 (VBI-2601), a protein-based HBV therapeutic vaccine, induced robust HBsAb responses that are strongly associated with increased HBsAg loss in subjects receiving PEG-IFNα |
| 2023-09-06 | VBI Vaccines Inc. | Results VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B vbivaccines.com ↗
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up |
| 2023-09-06 | Brii Biosciences Limited | Results Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B briibio.com ↗
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFN α increases HBsAg loss rate at the end of treatment and 12 weeks follow up |
| 2023-02-15 | VBI Vaccines Inc. | Results VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B vbivaccines.com ↗
VBI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed |
| 2023-02-15 | Brii Biosciences Limited | Results Brii Biosciences Announces Interim Results from Phase 2 Study Evaluating Combination BRII-835 and BRII-179 in Development for HBV Functional Cure briibio.com ↗
All cohorts achieved HBsAg reduction at the end of treatment with a mean decrease of -1.7 to -1.8 log 10 IU/mL. |
| 2021-06-23 | VBI Vaccines Inc. | Results Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021 vbivaccines.com ↗
Brii Biosciences (“Brii Bio”) and VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection. |
| 2021-06-23 | Brii Biosciences Limited | Results Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021 briibio.com ↗
Data demonstrate that BRII-179 (VBI-2601) induced both B cell (antibody) and T cell responses in chronically-infected hepatitis B (HBV) patients, and was well-tolerated with no safety signals observed |
| 2021-04-12 | VBI Vaccines Inc. | Results VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate vbivaccines.com ↗
Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179) |
All press releases naming this drug 26 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRII-179 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06650852 ↗ |
| Known as | VBI-2601 | “BRII-179 (VBI-2601) will be administered by intramuscular injection” NCT04749368 ↗ |
| Modality | Vaccine | “virus-like particle-based therapeutic vaccine (BRII-179)” PMID 40043858 ↗ Mar 2025 |
| Route | Intramuscular | “BRII-179 (VBI-2601) will be administered by intramuscular injection” NCT04749368 ↗ |